{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:40:25Z","timestamp":1781624425408,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>This meta-analysis investigates the incidence of intraocular inflammation (IOI) after intravitreal antivascular endothelial growth factor injections in neovascular age-related macular degeneration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic search was performed on Ovid MEDLINE, Embase, and Cochrane Central from January 2005 to April 2021. Randomized controlled trials comparing IOI after intravitreal bevacizumab, ranibizumab, brolucizumab, or aflibercept in neovascular age-related macular degeneration were included. Primary outcomes were sight-threatening IOI, final best-corrected visual acuity, and change in best-corrected visual acuity from baseline. Secondary outcomes included the incidence of other IOI events. Meta-analysis was performed using a random-effects model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 11,460 unique studies were screened, of which 14 randomized controlled trials and 6,759 eyes at baseline were included. There was no difference between agents for the risk of endophthalmitis and retinal vascular occlusion. Compared with aflibercept, brolucizumab had a higher incidence of generalized IOI (risk ratio = 6.24, 95% confidence interval = [1.40\u201327.90]) and vitreous haze\/floaters (risk ratio = 1.64, 95% confidence interval = [1.00\u20132.67]). There were no significant differences between comparators for other secondary end points.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>There was no difference in the risk of severe sight-threatening IOI outcomes between intravitreal antivascular endothelial growth factor agents. There was a significantly higher risk of generalized IOI after brolucizumab relative to aflibercept. Our results alongside other recent safety findings suggest the need for further investigation in the risk\u2013benefit profile of brolucizumab for the treatment of neovascular age-related macular degeneration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003582","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T18:06:18Z","timestamp":1666375578000},"page":"2134-2142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS"],"prefix":"10.1097","volume":"42","author":[{"given":"Nikhil S.","family":"Patil","sequence":"first","affiliation":[{"name":"Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan S.","family":"Dhoot","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"},{"name":"John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Department of Ophthalmology, St. Michael's Hospital\/Unity Health Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","first-page":"44","article-title":"Anti-VEGF drugs in the prevention of blindness","volume":"27","author":"Yorston","year":"2014","journal-title":"Community Eye Health J"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12886-018-0785-3","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials","volume":"18","author":"Nguyen","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/OPTH.S184706","article-title":"Brolucizumab","volume":"13","author":"Yannuzzi","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1080\/02713683.2020.1731832","article-title":"Comparison of the efficacy of brolucizumab with natural disease progression in wet AMD using clinical data from the phase III HAWK and HARRIER trials and modelled placebo data","volume":"45","author":"Agostini","year":"2020","journal-title":"Curr Eye Res"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion\u2013related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0301-4738.81023","article-title":"Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration","volume":"59","author":"Biswas","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5935\/0004-2749.20190043","article-title":"Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration","volume":"82","author":"Nunes","year":"2019","journal-title":"Arquivos Brasileiros de Oftalmologia"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"Subramanian","year":"2010","journal-title":"Eye"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"Subramanian","year":"2010","journal-title":"Eye"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"100989","DOI":"10.1016\/j.ajoc.2020.100989","article-title":"Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study","volume":"20","author":"Iyer","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:02:25Z","timestamp":1749319345000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003582"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003582","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}